Abstracts tagged "Rheumatoid Factor"

Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Luca Quartuccio¹, Sara Salvin², Laura Corazza¹, Saviana Gandolfo², Martina Fabris³ and Salvatore De Vita⁴, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Rheumatology Clinic, University of Udine, Udine, Italy, ³Clinic of Rheumatology, University of Udine, Udine, Italy, ⁴Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…
Abstract Number: 1207 • 2015 ACR/ARHP Annual Meeting
Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis
Miriam Gärtner, Mathias Schneeweiss, Josef S. Smolen and Klaus Machold, Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Antibody profiling encompassing rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) supports diagnosis in patients with Rheumatoid arthritis (RA). However, RF and ACPA are…
Abstract Number: 1559 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Medication Use Among Arab Patients with Rheumatoid Arthritis in Some Arab States
Karim Bayoumy¹, Soha Roger Dargham¹, Wessam Elhaq¹, Samar Al Emadi², Mohammed Hammoudeh², Basel Masri³, Hussein Halabi⁴, Humeira Badsha⁵, Imad Uthman⁶, Salah Mahdy², Robert Plenge⁷, Richa Saxena⁷, Marianthi Kapiri¹ and Thurayya Arayssi⁸, ¹Weill Cornell Medical College in Qatar, Doha, Qatar, ²Medicine, Hamad Medical Corporation, Doha, Qatar, ³Jordan Hospital, Amman, Jordan, ⁴Medicine, King Faisal Specialist Hospital and research center, Jeddah, Saudi Arabia, ⁵Al Biraa Arthritis and Bone Clinic, Dubai, United Arab Emirates, ⁶Internal Medicine, American University of Beirut, Beirut, Lebanon, ⁷The Broad Institute of MIT and Harvard, Program of Medical and Population Genetics, Cambridge, MA, ⁸Internal Medicine, Weill Cornell Medical College in Qatar, Doha, Qatar
Background/Purpose: Data on the clinical and genetic characteristics of Arab patients with Rheumatoid Arthritis (RA) is limited. Our aim is to report on the clinical…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 453 • 2014 ACR/ARHP Annual Meeting
In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA
Jerry A. Molitor¹, Bryan S. Michalowicz², Ryan T. Demmer³, Jane H. Buckner⁴, Mark H. Wener⁵ and William H. Robinson⁶, ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Department of Developmental and Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ³Epidemiology, Columbia Univ. Mailman School of Public Health, New York, NY, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Rheumatology & Lab Med, University of Washington, Seattle, WA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Periodontal disease (PD) and RA share the risk factors HLA DR B1 shared epitope (SE) and tobacco exposure (TE). PD may represent a risk…
Abstract Number: 408 • 2014 ACR/ARHP Annual Meeting
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
D. van Schaardenburg¹, Mairead Murphy², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose We have previously reported pilot data that patients who are only positive for 14-3-3η auto-antibodies (AAb) and negative for the 14-3-3η protein have a…
Abstract Number: 407 • 2014 ACR/ARHP Annual Meeting
Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers
Olga Zhukov¹, Jonnielyn Rivera¹, Charles M. Rowland², Joanna M. Popov¹ and Stanley J. Naides³, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Bioinformatics, Celera, Alameda, CA, ³Immunology, Quest Diagnostics, San Juan Capistrano, CA
Background/Purpose: The 14-3-3 family of chaperonin proteins consists of 7 isomers. The tissue distribution of the 14-3-3η (eta) isoform is limited to synovial tissue and…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…
Abstract Number: 372 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain
Raashid Luqmani¹, Klara Morsley², Anne Miller³, Christopher J. Edwards⁴, M. Kassim Javaid⁵, Daniel Prieto-Alhambra⁶, Rafael Pinedo-Villanueva^7,8, Manuel Medina Peralta⁹, Sebastian Calero Munoz⁹, Nigel Arden^10,11, Francesc Fina-Aviles⁹ and Cyrus Cooper¹², ¹Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ²Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ³Rheumatology, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ⁴University Hospital Southampton, Southampton, United Kingdom, ⁵Rheumatology, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁶NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ⁷NDORMS, University of Oxford, Oxford, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Institut Català de la Salut, Barcelona, Spain, ¹⁰NIHR Musculoskeletal Biomedical Research Unit University of Oxford, Oxford, United Kingdom, ¹¹University of Southampton, Southampton, United Kingdom, ¹²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom
Background/Purpose: To assess the sensitivity, specificity, and predictive values of rheumatoid factor (RF) as a test for rheumatoid arthritis (RA) in primary care, and to…
Abstract Number: 2021 • 2014 ACR/ARHP Annual Meeting
The Association Between Rheumatoid Factor and Cardiovascular Disease in Healthy Adults
Chisun Min¹, Mitsumasa Kishimoto¹, Gautam A. Deshpande², Shunya Kaneshita¹, Masei Suda¹, Yuri Ohara¹, Yoichiro Haji¹, Ryo Rokutanda¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi¹, Akira Takeda³, Yukio Matsui¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ³Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan
Background/Purpose Rheumatoid arthritis (RA) has been shown to be a risk factor for cardiovascular disease (CVD). Both elevated rheumatoid factor (RF) and anti-citrullinated protein antibodies…
Abstract Number: 1560 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
Frank Behrens^1,2, Michaela Koehm^2,3, Eva C. Scharbatke⁴, Bianca Wittig⁵, Marc Schmalzing⁴, Holger Gnann⁶, H M Lorenz⁷, Diamant Thaci⁸ and Harald Burkhardt^1,9, ¹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ²Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lübeck, Germany, ⁹Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose Osteoporosis is an important comorbidity in patients with rheumatic diseases, but risk factors for osteoporosis in Psoriatic Arthritis (PsA) patients have not been explored. …
Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting
Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis
Muhammad Imran¹, Shanley O'brien², Mark Hamblin³ and Mehrdad Maz⁴, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, Kansas University Medical Center, Kansas city, MO, ³Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
Abstract Number: 2394 • 2013 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Smoking Is Not Primarily Associated With Anti-Citrullinated Protein Antibodies, But With The Presence Of Multiple Autoantibodies
Ammar Muhammad¹, Tineke van Wesemael², Yuta Kochi³, Maria Mjaavatten⁴, Kirsten Wevers-de-Boer¹, Cornelia F. Allaart¹, Leendert A. Trouw¹, Akari Suzuki³, Kazuhiko Yamamoto⁵, Annette H.M. van der Helm-van Mil¹, Tom W.J. Huizinga¹, René E.M. Toes¹ and Diane van der Woude¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Smoking is associated with the presence of several autoantibodies in various autoimmune diseases. In rheumatoid arthritis (RA), smoking has been described to be specifically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].